Терапевтический архивThe review addresses publications on genetic polymorphisms that potentially impact the effectiveness of therapy with hypoglycemic drugs of the dipeptidyl peptidase-4 inhibitor group.
Iuliia G. Samoilova +10 more
doaj +1 more source
The role of dipeptidyl peptidase - 4 inhibitors in diabetic kidney disease
Frontiers in Immunology, 2015 Despite major advances in the understanding of the molecular mechanisms that underpin the development of diabetic kidney disease, current best practice still leaves a significant proportion of patients with end stage kidney disease requiring renal ...
Usha ePanchapakesan, Carol ePollock
doaj +1 more source
Need an add-on to metformin? Consider this [PDF]
, 2017 Review of: Ou SM, Shih CJ, Chao PW, et al. Effects of clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus. Ann Intern Med.
Lyon, Corey +2 more
core
Journal of Obesity & Metabolic Syndrome, 2017 Background : Dipeptidyl peptidase-4 (DPP-4) is an aminopeptidase that inhibits the enzymatic degradation of glucagon-like peptide-1, glucose-dependent insulinotropic polypeptides, neuropeptides, and various chemokines.
Ji Yeon Lee +4 more
doaj +1 more source
Neural Regeneration Research, 2019 Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 receptor agonists is a breakthrough in the field of neural regeneration research increasing glucagon like peptide-1 bioavailability, hence its neuroprotective activities.
Shaker A Mousa, Bassam M Ayoub
doaj +1 more source
The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3 [PDF]
, 2018 Aims To evaluate the effect of concomitant dipeptidyl peptidase IV inhibitor (DPPIVi) use on efficacy and safety of insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100) in people with type 2 diabetes on oral antihyperglycaemic drugs ...
Brito-Sanfiel, Miguel +7 more
core +4 more sources
COVID-19 and chronological aging : senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? [PDF]
, 2020 COVID-19, also known as SARS-CoV-2, is a new emerging zoonotic corona virus of the SARS (Severe Acute Respiratory Syndrome) and the MERS (Middle East Respiratory Syndrome) family.
Auwerx +30 more
core +2 more sources
Family C1 cysteine proteases: Biological diversity or redundancy? [PDF]
, 2003 Recent progress in the identification and partial characterization of novel genes encoding cysteine proteases of the papain family has considerably increased our knowledge of this family of enzymes.
Brömme D. +4 more
core +1 more source
Al-Mustansiriyah Journal of Pharmaceutical Sciences, 2013 Until 1995, only two options for pharmacologic treatment were available for patients with diabetes; sulfonylurea (for type 2 DM only) and insulin (for type 1 or 2).
Hassan Mohammed Abbas Al-Temimi +2 more
doaj +1 more source
Gastrointestinal endogenous proteins as a source of bioactive peptides : Doctor of Philosophy in Nutritional Sciences at Riddet Institute, Massey University, Palmerston North, New Zealand [PDF]
, 2016 Gastrointestinal endogenous proteins (GEP) were investigated as a source of bioactive peptides. In silico and in vitro methods were used singly or in combination to study GEP-derived peptides after simulated digestion.
Acharya, Prasannalakshmi
core